Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
#Artificial Intelligence In Drug Repurposing Market Value Growth And Long-Term Outlook#_x000D_
The market size for artificial intelligence in drug repurposing has experienced rapid expansion in recent years. This market is expected to increase from $1.05 billion in 2025 to $1.27 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 20.3%. The historical period’s growth can be attributed to several factors, including the escalating research and development costs in pharmaceutical development, the availability of public biomedical datasets, the advancement of computational biology tools, the necessity to accelerate the time to market for new therapies, and the growing collaborations between pharmaceutical companies and AI startups._x000D_
_x000D_
The artificial intelligence in drug repurposing market is projected to experience substantial expansion over the upcoming years, with an anticipated growth to $2.63 billion in 2030 at a compound annual growth rate (CAGR) of 20.1%. This expected growth is driven by factors such as the rise of AI-assisted clinical decision support, the expanding application of generative AI for molecule insights, the urgent requirement for quicker repurposing during health crises, the broadening of real-world evidence analytics, and increasing funding into precision medicine pipelines. Key trends anticipated during this period encompass AI-driven drug-target matching utilizing multi-omics data, repurposing pipelines leveraging knowledge graph discovery, accelerated virtual screening and trial simulation, federated learning facilitating cross-institution research, and explainable AI for informed clinical repurposing decisions._x000D_
_x000D_
#Get A Free Sample Report With In-Depth Market Insights:#_x000D_
_x000D_
#Artificial Intelligence In Drug Repurposing Market Demand Drivers Opening New Revenue Streams#_x000D_
The increasing need for precision medicine is anticipated to accelerate the expansion of the artificial intelligence in drug repurposing market going forward. Precision medicine represents a healthcare strategy that customizes disease prevention and treatment based on an individual’s unique genes, behaviors, and environment. The rising desire for personalized treatments is a key factor boosting precision medicine, as patients and healthcare providers increasingly seek therapies specifically adapted to individual genetic and lifestyle profiles for enhanced effectiveness and reduced side effects. AI-driven drug repurposing plays a crucial role in improving precision medicine by uncovering existing drugs that align with an individual’s genetic or molecular characteristics, thereby enabling more accurate and tailored treatment solutions. For illustration, in February 2024, as reported by the Personalized Medicine Coalition, a US-based nonprofit, the FDA authorized 16 personalized therapies targeting rare diseases in 2023, a significant increase from the six approvals issued in 2022. Thus, the growing demand for precision medicine is propelling the growth of the artificial intelligence in drug repurposing market._x000D_
_x000D_
#Artificial Intelligence In Drug Repurposing Market Segment Breakdown: Which Categories Lead On Revenue?#_x000D_
The artificial intelligence in drug repurposing market covered in this report is segmented – _x000D_
_x000D_
1) By Component: Software And Platforms, Services_x000D_
2) By Technology: Machine Learning Or Deep Learning, Natural Language Processing (NLP), Knowledge Graphs And Network-Based Artificial Intelligence, Generative Artificial Intelligence And Large Language Models (LLMs), Computer Vision_x000D_
3) By Deployment: Cloud-Based, On-Premises_x000D_
4) By Therapeutic Area: Oncology, Neurology, Cardiovascular Diseases, Infectious Diseases, Immunology, Metabolic Disorders, Rare Diseases_x000D_
5) By End-User: Pharmaceutical And Biotechnology Companies, Contract Research Organizations (CROs), Academic And Research Institutes, Healthcare Providers, Other End-Users_x000D_
_x000D_
Subsegments:_x000D_
1) By Software And Platforms: Predictive Analytics Tools, Machine Learning Frameworks, Data Integration Systems, Drug Discovery Platforms, Clinical Trial Simulation Tools_x000D_
2) By Services: Consulting Services, Data Management Services, Model Training And Optimization Services, Implementation And Integration Services, Support And Maintenance Services_x000D_
_x000D_
#Artificial Intelligence In Drug Repurposing Market Trends Powering Strategic Industry Growth#_x000D_
Companies within the artificial intelligence in drug repurposing market are increasingly adopting sophisticated technologies, such as computational drug repositioning systems, which are designed to systematically uncover novel therapeutic uses for existing drugs through data-driven analysis of scientific literature and biological data. These platforms leverage artificial intelligence, machine learning, and data mining techniques for the systematic analysis of available drugs, compounds, and biological information. An illustrative example is the November 2023 announcement by Tempus, a US-based AI-driven precision medicine provider, of a multi-year strategic collaboration with Recursion, a US-based clinical-stage biotechnology company, a deal worth up to $160 million over five years. This partnership grants Recursion access to Tempus’ comprehensive collection of de-identified, multimodal oncology data, aiding the development of biomarker-driven therapeutics. Utilizing Tempus’ vast patient datasets in conjunction with Recursion’s AI-powered discovery abilities, the alliance aims to bolster oncology drug repurposing efforts, illustrating how cutting-edge computational platforms, when merged with real-world clinical data, can expedite the identification of new treatment avenues._x000D_
_x000D_
#Artificial Intelligence In Drug Repurposing Market Leading Players And Competitive Positioning#_x000D_
Major companies operating in the artificial intelligence in drug repurposing market are IBM Corporation, Evogene Ltd., Ginkgo Bioworks Holdings Inc., BioAge Labs Inc., Insilico Medicine Inc., BostonGene Corporation, ISOMORPHIC LABS, Recursion Pharmaceuticals Inc., Deep Genomics Inc., Healx Ltd., Owkin Inc., BullFrog AI Holdings Inc., Aicura Medical GmbH, Kantify, Ignota Labs Ltd., OrphAI Therapeutics, Nabla Bio, Atomwise Inc., BioXcel Therapeutics Inc., Graph AI. _x000D_
_x000D_
#View The Full Artificial Intelligence In Drug Repurposing Market Report:#_x000D_
_x000D_
#Artificial Intelligence In Drug Repurposing Market Regional Split: Which Areas Are Fueling Growth?#_x000D_
North America was the largest region in the artificial intelligence in drug repurposing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in drug repurposing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
#Reach Out To Our Team:#_x000D_
_x000D_
The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_
Americas: +1 310-496-7795_x000D_
Asia: +44 7882 955267 & +91 8897263534_x000D_
Europe: +44 7882 955267_x000D_
Email us at: marketing@tbrc.info_x000D_
_x000D_
#Follow us on:#_x000D_
_x000D_
LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
